Show simple item record

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.

dc.contributor.authorJohn, A
dc.contributor.authorVick, J
dc.contributor.authorSarker, S
dc.contributor.authorMiddleton, E
dc.contributor.authorCartwright, E
dc.contributor.authorManickavasagar, T
dc.contributor.authorMcMahon, D
dc.contributor.authorTokaca, N
dc.contributor.authorPopat, S
dc.coverage.spatialUnited States
dc.date.accessioned2024-08-13T13:42:11Z
dc.date.available2024-08-13T13:42:11Z
dc.date.issued2024-07-01
dc.identifierARTN 100689
dc.identifierS2666-3643(24)00059-6
dc.identifier.citationJTO Clinical and Research Reports, 2024, 5 (7), pp. 100689 -en_US
dc.identifier.issn2666-3643
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6354
dc.identifier.eissn2666-3643
dc.identifier.eissn2666-3643
dc.identifier.doi10.1016/j.jtocrr.2024.100689
dc.identifier.doi10.1016/j.jtocrr.2024.100689
dc.description.abstractNeurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.
dc.formatElectronic-eCollection
dc.format.extent100689 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofJTO Clinical and Research Reports
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectALK
dc.subjectAdverse event
dc.subjectCase report
dc.subjectLorlatinib
dc.subjectNon–small cell lung cancer
dc.subjectPsychosis
dc.titleSuccessful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-05-12
dc.date.updated2024-08-13T13:38:34Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.jtocrr.2024.100689en_US
rioxxterms.licenseref.startdate2024-07-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/39091593
pubs.issue7
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.jtocrr.2024.100689
pubs.volume5
dc.contributor.icrauthorPopat, Sanjay
icr.provenanceDeposited by Mr Arek Surman on 2024-08-13. Deposit type is initial. No. of files: 1. Files: Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC A Case Report. .pdf


Files in this item

Thumbnail
Name:
Successful Lorlatinib Rechallenge ...
Size:
499.1Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/